68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism
NCT05131061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2022-07-15
Summary
To evaluate the value of 68Ga-Pentixafor PET/CT in the diagnosis of primary aldosteronism subtype
Conditions
- Primary Aldosteronism
Interventions
- DIAGNOSTIC_TEST
-
68Ga-Pentixafor PET/CT imaging
68Ga-Pentixafor PET/CT imaging
Sponsors & Collaborators
-
The Affiliated Hospital Of Southwest Medical University
collaborator OTHER -
Qifu Li
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-11-11
- Primary Completion
- 2022-05-01
- Completion
- 2022-05-31
Countries
- China
Study Locations
More Related Trials
-
Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
NCT06773663 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Non Invasive Imaging Methods for Detecting PA：a Clinical PET Study of 18F-Pentixather
NCT06581744 ·Status: RECRUITING ·Phase: NA
-
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
NCT05673031 ·Status: RECRUITING
-
Gallium-68 Labeled Pentixafor PET/CT in Adrenal Masses
NCT04859959 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
68Ga-Pentikra PET/CT Imaging Study in Healthy Subjects
NCT06856109 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer
NCT06165874 ·Status: RECRUITING ·Phase: NA
-
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
NCT06690957 ·Status: RECRUITING
-
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
NCT01527058 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
NCT06608160 ·Status: RECRUITING
-
68Ga-PSMA PET in the Renal Cell Carcinoma
NCT04987086 ·Status: RECRUITING ·Phase: NA
-
Imaging Correlates of Renal Cell Carcinoma Biological Features
NCT01665703 ·Status: COMPLETED ·Phase: NA
-
Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism
NCT06478875 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
NCT07102056 ·Status: NOT_YET_RECRUITING
-
Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer
NCT06203613 ·Status: RECRUITING ·Phase: NA
-
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
NCT04525612 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
68Ga-PSMA PET/CT for Ra223 Assessment
NCT04951817 ·Status: RECRUITING ·Phase: NA
-
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
NCT07288931 ·Status: RECRUITING ·Phase: NA
-
Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
NCT05006326 ·Status: UNKNOWN ·Phase: NA
-
SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs
NCT06344832 ·Status: NOT_YET_RECRUITING
-
Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors
NCT07254104 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer
NCT05508126 ·Status: RECRUITING
-
Dual-Tracer Theranostic PET
NCT05680675 ·Status: COMPLETED ·Phase: NA
-
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
NCT02810600 ·Status: COMPLETED
-
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
NCT04041882 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
18F-LN1 PET/CT in Urothelial Carcinomas
NCT06120413 ·Status: RECRUITING